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ABSTRACT
Trypanosoma cruzi carbonic anhydrase (TcCA) has recently emerged as an interesting target for the design
of new compounds to treat Chagas disease. In this study we report the results of a structure-based virtual
screening campaign to identify novel and selective TcCA inhibitors. The combination of properly validated
computational methodologies such as comparative modelling, molecular dynamics and docking simula-
tions allowed us to find high potency hits, with KI values in the nanomolar range. The compounds also
showed trypanocidal effects against T. cruzi epimastigotes and trypomastigotes. All the candidates are
selective for inhibiting TcCA over the human isoform CA II, which is encouraging in terms of possible
therapeutic safety and efficacy.
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Carbon dioxide (CO2) is a product of many metabolic aerobic
processes in different organisms. It has a relatively low solubility
in water, but it reacts with this solvent (at the neutral pH) to pro-
duce bicarbonate anion and protons. These two ions play a crucial
role in maintaining pH homeostasis in living systems and their
equilibration with CO2 is controlled by the activity of the enzymes
Carbonic Anhydrase (CA, EC 4.2.1.1)1–5. CAs are extremely efficient
catalysts, and they are widespread in organisms all over the phylo-
genetic tree. So far, there are eight genetically distinct families
categorised as a-, b-, c-, d-, f-, g-, H- and d-CAs6–12. In mammals,
there are 16 isoforms known to date, that belong to the a-CA
family and some of them have been studied as molecular targets
to treat human diseases8–12. Traditionally, CA inhibitors are
employed as diuretic and antiglaucoma drugs, but other clinical
applications have been proposed, including the treatment of can-
cer, obesity and epilepsy13–19. Regarding neglected protozoan dis-
eases, such as the American trypanosomiasis, CA is emerging as a
new therapeutic target, with its inhibitors being probably able to
provide an increased efficacy and safety in comparison with the
current treatments20. American trypanosomiasis, also known as
Chagas disease, is caused by the parasite Trypanosoma cruzi21. It
was first described by Carlos Chagas more than a century ago and
it affects about 8 million people worldwide22. The disease is char-
acterised by two phases: an initial acute stage which usually goes
undetected because it lacks specific symptoms and; a chronic
stage that may remain asymptomatic but evolves to clinical mani-
festations in specific organs (heart, digestive system and/or ner-
vous system) in about 30% of the patients23. The therapeutic
arsenal to treat Chagas is composed of only two drugs, benznida-
zole and nifurtimox23. They were discovered more than 40 years
ago, and they are mostly active in the acute phase of the disease.
Their limited efficacy in the chronic phase as well as their consid-
erable toxicity fostered the efforts to explore the molecular biol-
ogy of T. cruzi aiming to discover new therapeutic targets. In this
scenario, the inhibition of protozoan CAs showed up recently as
an interesting option for the future treatment of Chagas disease,
as well as other neglected pathologies like Leishmaniasis20.
At present, only one T. cruzi carbonic anhydrase (TcCA) has
been described in the genome of the parasite. TcCA has recently
been cloned and characterised by Pan et al.24 It belongs to the
a-CA family and shares the active site topology with the catalytic
a-isoforms found in mammals: the three His residues coordinating
with one Zinc ion, and a fourth coordination position occupied by
a water molecule at acidic pH (<7) or by a hydroxide ion at
higher pH values20,24. The role of the enzyme in the pathogen is
still poorly understood, but it is known that TcCA shows a very
high catalytic activity24,25–29. It has been hypothesised that TcCA is
involved in the proliferation of the parasite when it is in the epi-
mastigote stage20. This assumption was supported by some in
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vitro and ex vivo studies that demonstrated the ability of TcCA
inhibitors to inhibit epimastigote proliferation.
Regarding the chemical structure of CA inhibitors, sulphona-
mides are the main class of compounds that interacts with CAs in
mammals, especially with CA II (which is, by far, the most studied
isoform)13–19. The classical mechanism of inhibition involves the
interaction of the sulphonamide nitrogen atom with the Zinc ion,
which places the inhibitors in the position originally occupied by
water (or the hydroxide ion)13–19,30. TcCA is also inhibited by other
compound families, such as thiols and hydroxamates20. Moreover,
molecules from these two classes showed better potency and
selectivity in vitro compared to sulphonamides, as well as promis-
ing in vivo profiles, by inhibiting the three phases of the patho-
gen’s life cycle (trypomastigote, amastigote and epimastigote)24.
Following these previous investigations, we investigate here the
capacity of a new set of compounds to inhibit TcCA. One of the
main challenges in the development of new CA inhibitors is to
find selectivity against the specific isoforms involved in the dis-
ease, to avoid tolerance problems and to improve the therapeutic
safety. Therefore, the selection of the candidates for biological
assays was guided by the results of a virtual screening protocol
applied to a set of compounds that share a zinc binding function
(sulphamides, and their bioisosters sulphamates and sulphona-
mides) and have low inhibitory activity against the ubiquitous
human isoform CA II, which could be considered as an anti-target.
Our investigation initiated with the construction of three-
dimensional models of TcCA, since the experimental structure of
the target is not yet available. A test set of 87 known TcCA inhibi-
tors was then compiled from literature and used to select the
best docking model for the virtual screening, based on the correl-
ation between the docking score and the experimentally deter-
mined pKI. Finally, an in-house dataset of 255 compounds was
screened and 10 compounds were tested against TcCA. Anti-
trypanosomal effects were also investigated for the selected candi-
dates. Information about the identity of the structures of the test
set (Table S1) and the dataset for screening is given as supporting
information (Table S2) (see Supplementary information for details)
Materials and methods
Protein structure modelling
We applied the Meier et al.31 algorithm as implemented in the
HHPred Server32 to construct our initial model of the enzyme. The
sequence of TcCA was retrieved from Uniprot (Q4CVY4)33. A multi-
template model was generated combining the top 10 templates
ranked by its alignment score. The quality of the model was eval-
uated with the metrics provided by the server, Molprobity and the
QMEAN scoring functions32. Then, the macrostructure was submit-
ted to an iterative refinement process, combining Rosetta and
Molecular Dynamics (MD) simulations. For that purpose, we used
Rosetta’s Fast Relax algorithm with the metalloproteins modifica-
tion, which imposes constraints on the Zinc ion and its coordinat-
ing residues to preserve the coordination geometry during the
simulation34–37. Briefly, the protocol consists of alternating cycles
of rotamer repacking and gradient-based energy minimisation,
increasing the repulsive contributions within each cycle. After gen-
erating 100 new refined models, the top scoring decoy was
selected as the starting point for MD simulations.
MD simulations were carried out with the Amber16 package38,
using the FF14SB force field and the Zinc AMBER force field
(ZAFF) modification designed for 4-coordinated Zinc metal
centres39. Because the three His residues that coordinate with the
zinc ion in human CA are also conserved in TcCA, we assumed a
tetrahedral coordination for the Zinc atom and a water molecule
was manually placed in the fourth vertex to fulfil the coordination
geometry. Thus, the centre ID No. 6 in the ZAFF force field
was selected to set the parameters, which were derived by Mertz
et al. from human CA-II crystal structure 1CA2 using the
MCPB program39.
The structure was solvated in an octahedral box of TIP3P water
molecules, and Cl ions were added to neutralise the system.
Minimisation of the system was performed in four sequential
steps. First, only hydrogen atoms were minimised. Second, only
the solvent around the protein was allowed to move. Third, only
protein side chains and solvent were minimised, fixing the pos-
ition of the protein backbone atoms. Finally, the whole system
was minimised with no constraints. Every minimisation stage
involved 2500 steepest descent steps, followed by 7500 steps of
conjugate gradient. Then, the system was carefully heated to
298.15 K and equilibrated in six consecutive steps, starting in NVT
conditions and then switching to an NPT ensemble to equilibrate
the system density, progressively relieving constraints to achieve a
proper equilibration. A total of 50 ns was simulated, monitoring
the protein backbone RMSD as a simulation convergence criterion,
and 10 representative snapshots were extracted by clustering ana-
lysis. For that purpose, the whole trajectory was clustered using
the K-means algorithm implemented in cpptraj, fixing the number
of clusters (K¼ 10) and choosing the cluster centroid as the repre-
sentative structure in each case. Finally, all the selected snapshots
were subjected to a later refinement step using Rosetta’s Fast
Relax protocol described before34–37, to sample high-quality
decoys around the starting conformation. These 10 final TcCA
structural models were used for docking simulation.
Construction of the dataset and validation of the
docking models
A validation set of 87 molecules tested against the TcCA was com-
piled from literature20. It includes compounds with different
chemical structures but mostly presenting sulphonamides, thiols
and hydroxamates as Zinc binding functions. The activity values
(KI) of the compounds range between 0.51 and 84,000 nM. These
reported activities were transformed to pKI values (Table S1).
Benzoxaboroles described by Nocentini et al.40 were excluded
from the dataset because the docking forcefield does not include
parameters for boron atoms. For each molecule, the most abun-
dant species at pH 7.4 was calculated with ChemAxon41, consider-
ing tautomerization and resonance effects. Finally, 5000 steps of
geometry optimisation were carried out with the MMFF94S force
field, to get reasonable starting geometries. It is worth noticing
that thiol compounds were predicted to be deprotonated at the
given pH, with the negative charge stabilised by a nitrogen atom
from an adjacent heteroaromatic ring that is present in these mol-
ecules. The docking calculations were run with AutoDockZN42, a
software that includes modifications of the classic AutoDock4
force field with specific parameters for the zinc ion. This forcefield
has proven to overcome the performance of the original
AutoDock443 for docking small molecules into Zinc metallopro-
teins, in both binding energy estimation and pose prediction. The
grid maps were constructed centred on the Zinc atom for every
TcCA model with Autogrid 4.2.643. They covered 60 points in each
dimension from the Zinc centre, with a spacing of 0.375 Å. The
docking simulations were run by considering a population size of
300 and an elitism of 1. We performed 100 runs of the
Lamarckian Genetic Algorithm with AutoDock4.243. The scoring
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power of every docking model (combination of docking pro-
gramme and TcCA structural model) was evaluated by calculating
the Pearson correlation coefficient (Pearson’s r) between the dock-
ing scores and the pKI values for all the compounds in the valid-
ation set. Additionally, we evaluated the ranking power of the
models by calculating Kendall’s rank correlation coefficient (Tau B)
and Spearman’s rank correlation coefficient (Rho).
In order to evaluate the model’s performance as a classifier,
compounds were defined either as active or inactive based on
the reported KI value. To this end, compounds with a KI value
lower than 1 lM were considered as actives. Then, the Area
Under the Receiver Operating Characteristic Curve (ROC-AUC)
was calculated as a metric to evaluate the discriminating power
of the model. Figure 1 shows a schematic representation of the
methods used in this investigation to create and validate the
structure-based predictive model of TcCA for the virtual screen-
ing campaign.
Virtual screening
The previously described docking protocol was selected to screen
an inhouse library of 255 compounds (Table S2). Some of these
compounds were synthesised in our lab44–46, whilst others were
commercial compounds like the artificial sweeteners cyclamate
and acesulphame. Among top scoring hits, 10 structures were
selected for biological evaluation. All the candidates were tested
before as human CA II inhibitors and they showed poor inhibitory
potency in this mammalian isoform46–48. As previously mentioned,
CA II is ubiquitous in humans and it was considered as an anti-
target in this investigation, since we are looking for selective
inhibitors of the parasite isoform.
Biological assays
TcCA inhibition studies
An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow
instrument has been used to assay the catalytic activity of various
CA isozymes for CO2 hydration reaction
49. Phenol red (at a con-
centration of 0.2mM) was used as indicator, working at the
absorbance maximum of 557 nm, with 10mM Hepes (pH 7.5) as
buffer, 0.1M Na2SO4 (for maintaining constant ionic strength), fol-
lowing the CA-catalyzed CO2 hydration reaction for a period of
10 s at 25 C. The CO2 concentrations ranged from 1.7 to 17mM
for the determination of the kinetic parameters and inhibition
constants. For each inhibitor at least six traces of the initial 5–10%
of the reaction have been used for determining the initial velocity.
The uncatalyzed rates were determined in the same manner and
subtracted from the total observed rates. Stock solutions of inhibi-
tors (10mM) were prepared in distilled-deionised water and dilu-
tions up to 1 nM were done thereafter with the assay buffer.
Enzyme and inhibitor solutions were pre-incubated together for
15min (standard assay at room temperature) prior to assay, to
allow for the formation of the enzyme–inhibitor complex. The
inhibition constants were obtained by non-linear least-squares
methods using PRISM 3 and the Cheng–Prusoff equation, as
reported earlier40,50–72. All CAs were recombinant proteins pro-
duced as reported earlier by our group24.
Biological activity against T. cruzi epimastigotes
For all biological assays, stock and working solutions of the candi-
date drugs were prepared using DMSO as solvent and all condi-
tions were tested in triplicate.
Epimastigotes of the Y strain of T. cruzi were cultured at 28 C
in BHT medium supplemented with 20lg/ml haemin, 10% heat-
inactivated foetal bovine serum (FBS), 100 mg/ml streptomycin and
Figure 1. Schematic illustration of the methods involved in the construction of the model for the virtual screening. The progress of the investigation is described as a
cyan circle in each step of the molecular modelling.
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100U/ml penicillin. The antiproliferative activity of the candidates
was tested at 50mM concentration in cultures initiated at 107
cells/ml. Untreated controls were performed under the same cul-
ture conditions with equal concentrations of DMSO as for candi-
date drugs. After 3 and 7 d, the number of viable parasites was
counted using a haemocytometer chamber under light micro-
scope and results were expressed as percentage respect of the
untreated controls73.
Biological activity against T. cruzi trypomastigotes
Trypomastigotes of T. cruzi were purified at the parasitemia peak
from peripheral blood of mice infected with the RA strain.
Trypomastigotes (1 105 per well) were cultured in a 96 well-plate
(final volume 200ll) in RPMI medium supplemented with 10%
FBS at 37 C in 5% CO2 atmosphere. After 24 h motile parasites
were counted in haemocytometer chamber under the light micro-
scope74. Results were expressed as % viability of trypomastigotes
(respect to control) at 20 mM of the hits. Controls were performed
under the same culture conditions with equal concentrations of
DMSO as for candidate drugs. The negative control was cultured
with PBS and the positive control was cultured with Benznidazole
(20mM). The animal care for the experimental protocols was con-
ducted in accordance with the guidelines for the care and use of
laboratory animals approved by the Ethical Committee of the
Faculty of Medicine of the University of Buenos Aires.
Results and discussion
Construction of TcCA models
TcCA has been recently cloned and characterised by Pan et al.24
As mentioned before, the three His residues coordinating the Zinc
ion are conserved in the active site of TcCA, with the fourth
coordination position occupied by a water molecule (or by a
hydroxide ion, depending on the pH). Like human CA II, TcCA
exerts a high catalytic activity, and the gatekeeping residues
Glu106 and Thr199 are well conserved8–12. However, the proton
shuttle His64 is absent in TcCA isoform. Despite several CA struc-
tures of many organisms have been crystallised so far, there is not
a good template to perform a comparative modelling of TcCA.
There are 924 structures of CAs deposited in the Protein Data
Bank (PDB)75, but all of them have sequence identities lower than
30% with TcCA. In this situation, the combination of multiple tem-
plates generally increases the quality of the resultant model, but
only when the correct templates are combined since there is a
trade-off between the number of sequences included and the
noise introduced in the restraints. One possible approach to
address this challenge was recently proposed by Meier et al.31
and used in this investigation. They introduced a modification in
the MODELLER algorithm, using probability theory to combine the
density functions of individual template restraints76.
The multiple sequence alignment is provided as Supporting
Information (Figure S1), including the PDB ID and UNIPROT ID of
each template selected. The final model is 261 amino acids long,
spanning from residue 56 to 316 of the target sequence. The
structural quality metrics are summarised in Table 1 for every
intermediate structure of the modelling pipeline, from the raw
model generated by the HHPred server to the refined MD snap-
shot selected as the best TcCA model for docking (the criteria for
this selection was included in the next section). The quality of the
models was estimated with the QMEAN scoring function, and its
stereochemical correctness and all-atoms contacts were evaluated
with the Molprobity software.
The raw model produced by Modeller shows the poorest qual-
ity, whereas Rosettas refined model of the best snapshot
(17423_refined in Table 1) is the most correct in both geometric
and energetic evaluations. The normalised QMEAN4 value for the
final model is similar to the scores achieved in high resolution X-
ray structures of comparable size, and the per-residue energy ana-
lysis shows that the problematic portions of the model are
beyond the defined docking site (Figure S2). Figure 2 shows the
overall architecture of the final TcCA model, which was con-
structed based on the multi-template strategy and subsequently
refined by iterative Rosetta-MD simulations. Coordinates of the
model have been included as Supporting Information.
Validation of the docking protocol for TcCA virtual screening
Once we obtained an ensemble of TcCA models, the next step
was the selection of the best docking conditions for the virtual
screening. For that purpose, we analysed the ability of the soft-
ware to correlate the docking scores with the pKI values of the
compounds of the validation set. We docked the validation set
Table 1. Values of the parameters achieved in the structure quality evaluation of the different models of TcCA.
Metric/model HHPred raw HHPred refined Snap 17423 Snap 17423_refined
QMEAN4 6.04 1.60 4.06 0.96
Molprobity 3.57 1.83 2.04 1.81
Ramachandran allowed 95.4 98.1 95.8 98.1
Clash score 136.37 5.43 2.71 4.93
Figure 2. Final model of TcCA achieved from multi-template comparative model-
ling and subsequent iterative Rosetta-MD refinement. Histidine residues of the
active site are highlighted in green for carbon atoms and in blue for nitrogen
atoms. The zinc ion is represented as a non-bonded sphere in grey.
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into the final Rosetta’s refined models of the target. Bootstrap
sampling was applied to the data to calculate median values and
its associated confidence intervals to compare between different
models. The lowest energy pose from all the runs was chosen as
the binding mode for each structure. Other criteria would be to
consider the lowest energy pose from the most populated cluster,
but we found that these conformations oriented the zinc-binding
function outside the binding site for some compounds of
the dataset.
We did not expect a perfect correlation between the Ki values
and the scores due to the known limitations of docking scoring
functions to predict absolute binding energies, especially when
using protein models instead of crystal structures. Moreover, there
are experimental errors and biological variability inherent to all
bioactivity data that impacts on the final correlations.
Nevertheless, these metrics can be applied to compare between
different protein/docking models to select the best one under dif-
ferent conditions.
Figure 3 shows the statistical parameters in a conditional violin
plot for every protein model, considering Pearson’s R between the
docking scores and the pKI values. According to the results, we
decided to use as target model the snapshot 17423_r, since it
achieved the best correlation metrics for the structures of the val-
idation set. All the metrics calculated for every protein model are
summarised in Table S3.
Additionally, ROC curves were constructed to evaluate the cap-
acity of the models to discriminate known inhibitors from non-
inhibitors. The ROC curves plot the sensitivity of the model (true
positive rate) as a function of the false positive rate
(1 specificity) at various threshold settings. It could be inter-
preted as the probability that a classifier (like the docking score)
ranks a randomly chosen active compound higher than a ran-
domly chosen inactive one77,78. Accordingly, a perfect classifica-
tion of compounds would be represented in the graph by a line
that starts from the origin, reaches vertically the upper left corner,
and then goes to the upper right corner78. The area under the
curve (AUC) will be equal to one for this ideal performance while
an AUC of 0.5 will represent a random selection of active com-
pounds. Figure 4 shows the ROC curve obtained for the best
docking model selected for the virtual screening. The black line
represents a random classifier whose AUC-ROC is 0.5, whereas the
AUC-ROC for our model is 0.915, which is very close to the opti-
mal value.
The virtual screening of our database with the refined model
17423_r identified 42 structures as possible TcCA inhibitors.
Among them, 10 compounds were selected for biological evalu-
ation (Figure 5). The criteria of choice were the docking scores
and the chemical structure of the candidates. It is important to
note that human examination of the hits is highly recommended
for the selection of the candidates, since it helps to reduce false
positives due to docking score artefacts and can lead to the dis-
covery of more potent hits than score prioritisation alone.
Compounds 1–8 are aminoester-derived sulphamides with differ-
ent substituents in the second nitrogen atom of the sulphamide
function. These compounds were tested before as human CA II
inhibitors, with poor results50–54. The biological results against
TcCA of this family would give us the opportunity to get informa-
tion about the structure-activity relationships. The set was com-
pleted with two artificial sweeteners, acesulphame and sodium
cyclamate, which also have low potency as human CA II inhibitors
and different scaffolds than the other selected candidates47,48.
Additionally, they are commercially available compounds
approved for human consumption.
Biological assays
Table 2 shows the results of the biological assays against the
enzyme and the parasite. Inhibition values against TcCA were
reported as inhibition constants (KI) and the corresponding values
against human CA II were also included for comparison. The
effects of the candidates with respect to the untreated controls
against T. cruzi epimastigotes (Y-strain) and trypomastigotes (RA-
strain) were also measured and included in the table.
Figure 3. Pearson’s R obtained from docking the validation set on every refined MD snapshot. The white dot represents the median value, and the black line height
represents the distance between the lower quartile (Q1) to the upper quartile (Q3), which is called the interquartile range (IQR). Violin plots show the probability dens-
ity of the data at different values as a kernel density estimation.
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Regarding the interaction with TcCA, most of the structures
showed interesting inhibitory effect against the enzyme, with KI
values in the nanomolar range. These results evidence the
predictive capacity of the docking model to identify TcCA inhibi-
tors. Particularly, sulphamide 5 is the most potent inhibitor of the
set, with a KI value of 0.26 lM. Sodium cyclamate, a widely used
Figure 4. ROC curve obtained for the final model applied in the virtual screening.
Figure 5. Candidates selected from the virtual screening.
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sweetener, showed to be a potent TcCA inhibitor too. Concerning
selectivity, both compounds are about 30 times more active
against the parasite target than the human CA II, which represent
an important aspect to be considered in future investigations.
Figure 6 shows the representation of the binding interaction of
compound 5 with the active site. The docking programme orients
one nitrogen atom of the sulphamide group towards the zinc ion,
whereas oxygen atoms acts as hydrogen bond acceptors for
THR201 and THR202 sidechain hydroxyl groups. Similar interac-
tions were achieved between the second nitrogen atom of the
sulphamide and the Tyr4 side chain. This residue is also involved
in positive aromatic interactions with the inhibitor.
Similarly, Figure 7 shows the representation of the interaction
proposed by docking between cyclamate and the active site of
TcCA. The nitrogen atom of the sulphamate function interacts
with the Zinc ion and their oxygen atoms behave as hydrogen
bonding acceptors from the Thr residues of the active site. The
cyclohexyl substituent attached to the N atom contributes to the
binding through hydrophobic interactions.
The effect of the candidates against T. cruzi epimastigotes,
the non-infective and proliferative stage, was tested at 50mM
(Table 2). Among the best two TcCA inhibitors of the set, sodium
cyclamate showed 20% of inhibition on the proliferation of epi-
mastigotes at the tested concentration (7th day). When sodium
cyclamate was tested against trypomastigote, one of the clinically
relevant stages of T. cruzi, this candidate inhibited parasite viabil-
ity by 50% at 20 mM.
Other compounds also showed good inhibition profiles against
both forms of the parasite, but they were poorer TcCA inhibitors.
The lack of correlation between the inhibitory effects on the
enzyme and the trypanocidal effects on the parasite may suggest
that other mechanisms of action besides CA inhibition are present.
Other possible explanations to the discrepancy may relate with
the drugs uptake kinetics by the parasite and/or biotransform-
ation/inactivation of the candidates.
Conclusions
We report the results of a target-based virtual screening for the
discovery of new inhibitors of TcCA with poor interaction with
hCA II. As the experimental structure of the target is not available,
we turned to the careful construction of multi-template three-
dimensional models, to select the best macrostructure for docking
simulation. The iterative combination of Rosetta and MD
Table 2. Biological data and docking scores achieved for compounds of the set.
Compound KI TcCA (nM) KI hCA II (nM)
a Selectivity ratio Docking score
% Proliferation. Epimastigotesb
% Viability. Trypomastigotes 24 hc3rd day of growth 7th day of growth
1 594.4 >10,000 >16.8 8.38 86 92 73
2 604.6 >10,000 >16.5 9.16 79 102 66
3 752.5 4957 >6.6 9.30 107 94 91
4 950.5 >10,000 >10.5 8.48 57 55 72
5 261.4 8528 >32.6 9.13 73 96 105
6 951.8 >10,000 >10.5 8.14 103 104 65
7 7250 8884 1.22 8.79 103 121 76
8 448.8 >10,000 >22.3 7.97 72 114 98
Acesulphame 2242 >20,000 >8.9 7.05 92 89 101
Sodium cyclamate 348.1 >10,000 >28.7 7.46 89 78 52
aInhibition constants against hCAII were taken from literature28–30.
bEpimastigotes of the Y strain of T. cruzi (candidates tested at 50mM).
cTrypomastigotes of the RA strain of T. cruzi (candidates tested at 20 mM).
Figure 6. (A) Best docking solution for the interaction of compound 5 within the active site of TcCA. Histidine and important residues of the active site are highlighted
in grey for carbon atoms, in red for oxygen atoms and in blue for nitrogen atoms. The zinc ion is represented as a non-bonded sphere in cyan. Colour code for com-
pound 5: Carbon atoms in green, Nitrogen atoms in blue, sulphur atoms in yellow and oxygen atoms in red. (B) Schematic representation of the interactions between
compound 5 and the active site of the TcCA model.
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simulations allowed us to significantly improve the quality of the
starting model, as reflected by the reported metrics. It is import-
ant to note that we have achieved target models with high qual-
ity despite the low sequence identity of the templates found for
their construction.
The docking calculations were fully validated through a test set
of compounds with reported activity against TcCA, which led us
to find a structural model with the best scoring power. By the
application of the model in a virtual screening campaign we iden-
tified sulphamides with high potency and selectivity against the
ubiquitous human CAII isoform. Additionally, the model selected
two commercial and widely used artificial sweeteners with abun-
dant toxicological data available. They share the sulphamate func-
tion, a bioisosteric partner of sulphamide as zinc-binding function.
The assays in parasites identified sodium cyclamate as the most
promising structure in terms of trypanocidal activity, reducing try-
pomastigote viability by 48% at 20mM. Further molecular model-
ling and SAR studies will be performed in future investigations, to
achieve a deeper knowledge about the molecular determinants of
the potency and selectivity against TcCA.
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